A rare pediatric disease designation for its achondroplasia treatment and a subsequent $200 million private placement boosted shares of Tyra Biosciences Inc. on Feb. 2 by 29.3%. Read More
The week closed out with two IPOs on their way in. Alto Neuroscience Inc. (NASDAQ:ANRO) and Fractyl Health Inc. (NASDAQ:GUTS) both debuted on Wall Street with offerings looking to raise combined $238.6 million. Read More
Innate immunity specialist Calluna Pharma Inc. has raised €75 million (US$81 million) in a series A to take forward neutralizing antibodies targeted against damage-associated molecular pattern (DAMP) proteins that are released when cells are injured, or attacked by a pathogen. Read More
The biopharma industry started 2024 on the upswing, with all four categories of financings tracked by BioWorld up in value compared to last January, and also up from December. In comparison to January 2023, IPO value soared 262%, follow-ons surged by 247%, public/other offerings saw a 381% rise, and private financings experienced a 21% bump. Read More
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aviceda, Bio-Thera, Genentech, Intellia, Novavax, Purple, RS Oncology, Ryvu, Sensorion. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allarity, GSK, Hutchmed, Inmagene, Novozymes, Sio Gene, Takeda, Vivet. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abeona, Adaptimmune, Biosyngen, Cytodyn, Neurobo, Theradaptive. Read More
